KLF14 and Atherosclerosis

KLF14 与动脉粥样硬化

基本信息

  • 批准号:
    9333689
  • 负责人:
  • 金额:
    $ 70.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2021-02-28
  • 项目状态:
    已结题

项目摘要

ABSTRACT Reverse cholesterol transport (RCT) is an important protective mechanism against atherosclerosis, in which plasma high-density lipoprotein cholesterol (HDL-c) interacts with macrophages in arterial wall and shuttles excess of cholesterol back to the liver. In macrophages, the cholesterol efflux activity is controlled by the expression of ATP-binding cassette (ABC) transporters ABCA1 and ABCG1. Upregulation of ABCA1/ABCG1 in macrophages increases cholesterol efflux activity to HDL particles and decreases atherosclerosis. Kruppel- like factor 14 (KLF14), identified by large genome-wide association studies, is strongly associated with HDL-c level, coronary heart disease (CHD). Our preliminary studies demonstrate that KLF14 increases plasma HDL-c level by modulating hepatic apolipoprotein (apoA-I) production. Intriguingly, we identified that perhexiline, which is clinically used to treat angina and heart failure, is a novel KLF14 activator. Perhexiline-mediated KLF14 activation attenuated atherosclerosis in apoE-deficiency mice. Interestingly, we found that KLF14 regulates cholesterol efflux by upregulation of ABCA1 and ABCG1 in macrophages, which contribute to the availability of cholesterol to apoA-I and HDL. However, perhexiline has sub-optimal pharmaceutical properties such as off-target toxicity, narrow therapeutic index and variable pharmacokinetics. We also demonstrated that synthetic high density lipoprotein (sHDL) nanoparticles could target delivery of drugs to atheroma. These sHDL has been tested in clinical trials at large doses and were found to be safe and have favorable pharmacokinetics. Furthermore, we have developed sHDL-mediated drug delivery platform for atherosclerosis treatment. In this proposal, we will: 1) Determine KLF14 regulates atherosclerotic regression by enhancing cholesterol efflux; 2) Develop sHDL nanoparticles as an efficient atheroma drug delivery system; 3) Determine the ability of sHDL nanoparticles mediated KLF14 activator delivery to promote atherosclerosis regression in vivo. The long-term goal of this project is to understand the function and underlying mechanism of KLF14 in atherosclerosis regression in order to design novel therapeutic strategies for treatment of atherosclerosis.
摘要 胆固醇逆向转运(RCT)是抗动脉粥样硬化的重要保护机制,其中 血浆高密度脂蛋白胆固醇(HDL-c)与动脉壁巨噬细胞相互作用, 过量的胆固醇回到肝脏。在巨噬细胞中,胆固醇流出活性由 ATP结合盒(ABC)转运蛋白ABCA 1和ABCG 1的表达。ABCA 1/ABCG 1的上调 在巨噬细胞中增加胆固醇流出到HDL颗粒的活性并减少动脉粥样硬化。克虏伯- 通过大规模全基因组关联研究发现,类因子14(KLF 14)与HDL-c密切相关 水平,冠心病(CHD)。我们的初步研究表明,KLF 14增加血浆HDL-c, 通过调节肝载脂蛋白(apoA-I)的产生来降低水平。有趣的是,我们发现了perhexiline, 临床上用于治疗心绞痛和心力衰竭,是一种新的KLF 14激活剂。哌克西林介导 活化KLF 14可减轻apoE缺乏小鼠的动脉粥样硬化。有趣的是,我们发现KLF 14 通过上调巨噬细胞中的ABCA 1和ABCG 1来调节胆固醇流出,这有助于 胆固醇对apoA-I和HDL的利用率。然而,perhexiline具有次优的药物特性 例如脱靶毒性、狭窄治疗指数和可变的药代动力学。我们还证明了 合成的高密度脂蛋白(sHDL)纳米颗粒可以靶向动脉粥样硬化的药物输送。这些sHDL 已在临床试验中以大剂量进行了测试,发现是安全的,并具有良好的药代动力学。 此外,我们还开发了sHDL介导的动脉粥样硬化治疗药物输送平台。在这 我们将:1)确定KLF 14通过增强胆固醇流出来调节动脉粥样硬化消退; 2) 开发sHDL纳米粒作为有效的动脉粥样硬化药物递送系统; 3)测定sHDL 纳米颗粒介导的KLF 14激活剂递送促进体内动脉粥样硬化消退。长期 该项目的目标是了解KLF 14在动脉粥样硬化中的功能和潜在机制 回归,以便设计用于治疗动脉粥样硬化的新的治疗策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YUQING Eugene CHEN其他文献

YUQING Eugene CHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YUQING Eugene CHEN', 18)}}的其他基金

Nitro-Fatty Acids and Cardiovascular Disease
硝基脂肪酸与心血管疾病
  • 批准号:
    10670429
  • 财政年份:
    2022
  • 资助金额:
    $ 70.24万
  • 项目类别:
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
血管周围脂肪组织褐变可预防胸主动脉瘤
  • 批准号:
    10580855
  • 财政年份:
    2022
  • 资助金额:
    $ 70.24万
  • 项目类别:
Browning of perivascular adipose tissue protects against thoracic aortic aneurysm
血管周围脂肪组织褐变可预防胸主动脉瘤
  • 批准号:
    10462357
  • 财政年份:
    2022
  • 资助金额:
    $ 70.24万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10652321
  • 财政年份:
    2021
  • 资助金额:
    $ 70.24万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10313701
  • 财政年份:
    2021
  • 资助金额:
    $ 70.24万
  • 项目类别:
Development of gene editing based therapy for cardiovascular diseases
开发基于基因编辑的心血管疾病疗法
  • 批准号:
    10441548
  • 财政年份:
    2021
  • 资助金额:
    $ 70.24万
  • 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
  • 批准号:
    10221773
  • 财政年份:
    2019
  • 资助金额:
    $ 70.24万
  • 项目类别:
IDOL and dyslipidemia in cardiovascular diseases
IDOL 与心血管疾病中的血脂异常
  • 批准号:
    10451711
  • 财政年份:
    2019
  • 资助金额:
    $ 70.24万
  • 项目类别:
KLF14 and Cardiovascular Disease
KLF14 与心血管疾病
  • 批准号:
    10319617
  • 财政年份:
    2017
  • 资助金额:
    $ 70.24万
  • 项目类别:
KLF14 and Cardiovascular Disease
KLF14 与心血管疾病
  • 批准号:
    10569551
  • 财政年份:
    2017
  • 资助金额:
    $ 70.24万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 70.24万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了